» Articles » PMID: 29912804

Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation

Overview
Journal Am J Clin Oncol
Specialty Oncology
Date 2018 Jun 19
PMID 29912804
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Radical cystectomy currently remains the standard of care for muscle-invasive bladder cancer. However, surgery can be associated with considerable morbidity and mortality, including the removal of the bladder. An alternative strategy is to preserve the bladder through concurrent chemoradiation following a maximal transurethral resection of the tumor. National protocols using a bladder-preservation approach have demonstrated disease-specific outcomes comparable to radical cystectomy in selected patients, but these results have not been replicated in previously reported population-based series. Here, we describe an outcomes analysis of patients with muscle-invasive bladder cancer treated with either radical surgery or bladder-preserving chemoradiation (BPCRT) for those patients meeting BPCRT criterion using the National Cancer Database (NCDB).

Materials And Methods: Using the NCDB, patients with American Joint Commission on Cancer clinical T2-3, N0, M0 urothelial carcinoma diagnosed between 2004 and 2013 were included for analysis. Only patients treated with definitive intent with either radical cystectomy or concurrent chemotherapy and radiation after a maximal transurethral tumor resection were included. Propensity-score matching was used.

Results: Among 8454 eligible patients, 7276 (86%) underwent radical cystectomy, and 1178 (14%) underwent BPCRT. Patients undergoing BPCRT were significantly older (median age, 77 vs. 68 y; P<0.001) and had higher Charlson-Deyo comorbidity scores (P=0.002). Using propensity-matched analysis, 1002 patients remained in each cohort, and there was no significant difference in survival found between the 2 cohorts (median overall survival, 2.7 vs. 3.0 y [P=0.20]; 4-year overall survival, 39.1% and 42.6% [P=0.15], for BPCRT and surgery, respectively). In addition, the hazard ratio (HR) of surgery versus BPCRT decreased over time, with an initial HR of 1.27 favoring BPCRT which decreased by a factor of 0.85 per year.

Conclusions: From 2004 to 2013, ∼14% of patients from the NCDB who potentially met bladder-preservation criteria underwent the procedure. Our propensity-matched analysis is the only report of its kind to demonstrate similar survival outcomes with bladder preservation when patients are properly selected. This study is also the first to demonstrate a dynamic HR between radical surgery and BPCRT over time.

Citing Articles

Survival After Radical Cystectomy for Bladder Cancer: Development of a Fair Machine Learning Model.

Carbunaru S, Neshatvar Y, Do H, Murray K, Ranganath R, Nayan M JMIR Med Inform. 2024; 12:e63289.

PMID: 39671594 PMC: 11694706. DOI: 10.2196/63289.


The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature.

Claps F, Biasatti A, Di Gianfrancesco L, Ongaro L, Giannarini G, Pavan N J Clin Med. 2024; 13(15).

PMID: 39124615 PMC: 11313590. DOI: 10.3390/jcm13154349.


Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.

Kang N, Feng Y, Lin K, Chen Y, Ho C, Yang C Cancer Med. 2024; 13(2):e6972.

PMID: 38379322 PMC: 10844988. DOI: 10.1002/cam4.6972.


Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection.

Chang Y, Wu Y, Tsan D, Yap W, Fan K, Chang J Adv Radiat Oncol. 2024; 9(1):101302.

PMID: 38260237 PMC: 10801638. DOI: 10.1016/j.adro.2023.101302.


Comparative Outcomes of Radical Cystectomy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Waraich T, Khalid S, Ali A, Kathia U Cureus. 2024; 15(12):e50646.

PMID: 38229790 PMC: 10790112. DOI: 10.7759/cureus.50646.


References
1.
Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R . Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996; 14(1):119-26. DOI: 10.1200/JCO.1996.14.1.119. View

2.
Kaufman D, Winter K, Shipley W, Heney N, Wallace 3rd H, Toonkel L . Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant.... Urology. 2008; 73(4):833-7. DOI: 10.1016/j.urology.2008.09.036. View

3.
Kaufman D, Winter K, Shipley W, Heney N, Chetner M, Souhami L . The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on.... Oncologist. 2000; 5(6):471-6. DOI: 10.1634/theoncologist.5-6-471. View

4.
Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

5.
Partridge E . The National Cancer Data Base: ten years of growth and commitment. CA Cancer J Clin. 1998; 48(3):131-3. DOI: 10.3322/canjclin.48.3.131. View